Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Diabetic Retinopathy
|
159 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.060 | 0.833 | 6 | 2010 | 2017 | ||||||
Coronary Artery Disease
|
1022 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.050 | 0.800 | 5 | 2010 | 2018 | ||||||
Coronary heart disease
|
769 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.050 | 1.000 | 5 | 2016 | 2018 | ||||||
Conventional (Clear Cell) Renal Cell Carcinoma
|
203 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.040 | 0.750 | 4 | 2017 | 2018 | ||||||
Renal Cell Carcinoma
|
182 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.040 | 0.750 | 4 | 2017 | 2018 | ||||||
Bladder Neoplasm
|
278 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.030 | 0.667 | 3 | 2017 | 2019 | ||||||
Carcinoma of bladder
|
290 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.030 | 0.667 | 3 | 2017 | 2019 | ||||||
Coronary Arteriosclerosis
|
440 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.030 | 1.000 | 3 | 2010 | 2018 | ||||||
Malignant neoplasm of urinary bladder
|
289 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.030 | 0.667 | 3 | 2017 | 2019 | ||||||
Malignant Neoplasms
|
1441 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.030 | 1.000 | 3 | 2014 | 2018 | ||||||
Neoplasms
|
1571 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.030 | 1.000 | 3 | 2012 | 2019 | ||||||
Primary malignant neoplasm
|
1374 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.030 | 1.000 | 3 | 2014 | 2018 | ||||||
Age related macular degeneration
|
390 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.020 | 2 | 2013 | 2016 | |||||||
Carcinoma of lung
|
995 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.020 | 1.000 | 2 | 2014 | 2014 | ||||||
cervical cancer
|
257 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.020 | 1.000 | 2 | 2015 | 2015 | ||||||
Cervix carcinoma
|
266 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.020 | 1.000 | 2 | 2015 | 2015 | ||||||
Endometriosis
|
207 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.020 | 0.500 | 2 | 2013 | 2020 | ||||||
Glycogen storage disease type II
|
80 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.020 | 2 | 2013 | 2016 | |||||||
Liver carcinoma
|
769 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.020 | 1.000 | 2 | 2017 | 2019 | ||||||
Malignant neoplasm of lung
|
1000 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.020 | 1.000 | 2 | 2014 | 2014 | ||||||
Malignant neoplasm of prostate
|
861 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.020 | 0.500 | 2 | 2013 | 2018 | ||||||
Malignant neoplasm of stomach
|
603 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.020 | 1.000 | 2 | 2012 | 2018 | ||||||
Malignant tumor of cervix
|
245 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.020 | 1.000 | 2 | 2015 | 2015 | ||||||
Primary malignant neoplasm of lung
|
981 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.020 | 1.000 | 2 | 2014 | 2014 | ||||||
Prostate carcinoma
|
858 | 0.570 | 0.680 | 6 | 43768652 | upstream gene variant | A/C;T | snv | 0.020 | 0.500 | 2 | 2013 | 2018 |